THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Schering-Plough Corporation (SGP)

3/22/2006 Proxy Information

Dr. Leder’s son, Ethan Leder, is chief executive officer of United BioSource Corporation (“UBC”). UBC was formed in November 2003 and is a provider of specialized pharmaceutical services, including pharmacoeconomic information and analysis. UBC has developed its business by acquisition of a number of existing companies since its formation. Schering-Plough, for many years, has obtained services from these companies (going back to a period prior to Dr. Leder joining the Schering-Plough Board or Ethan Leder becoming affiliated with these companies). During 2005, Schering-Plough business with these companies totaled approximately $2.3 million, which was between 3% and 4% of UBC’s annual gross revenues for fiscal year 2005. The Nominating and Corporate Governance Committee and the Board of Directors determined that Dr. Leder is not independent as a result of these transactions, in accordance with the New York Stock Exchange listing standards and the more restrictive Schering-Plough Board Independence Standard. Since joining the Board, Dr. Leder has never been a member of a Board Committee where independence is required.

3/14/2005 Proxy Information

Dr. Leder's son, Ethan Leder, is chief executive officer and the owner of approximately 13% of the equity of United Biosource LLP. In January 2004, United Biosource acquired MedTap International Inc., a provider of pharmacoeconomic analysis and information. Schering-Plough in the past has retained MedTap to provide services in connection with specific pharmacoeconomic projects and may do so in the future. In 2004, Schering-Plough paid MedTap $44,928 for pharmacoeconomic services.

Under the New York Stock Exchange Listing Standards and the more restrictive Schering-Plough Board Independence Standard this matter does not impair Dr. Leder's independence. The Nominating and Corporate Governance Committee and the Board of Directors, after reviewing this matter, have determined that Dr. Leder is independent. However, in respect of many of the Company's institutional investors, which have varying definitions of independence, Dr. Leder has not been assigned to any Committee whose members are required to be independent.

3/15/2004 Proxy Information

Dr. Leder's son, Ethan Leder, is chief executive officer and the owner of approximately 13% of the equity of United Biosource LLP. In January 2004, United Biosource acquired MedTap International Inc., a provider of pharmacoeconomic analysis and information. Schering-Plough in the past has retained MedTap to provide services in connection with specific pharmacoeconomic projects and may do so in the future. In 2003, Schering-Plough paid MedTap $153,308 for pharmacoeconomic services.

3/31/2003 Proxy Information

The Corporation entered into a contract, which was terminated in December 2002, with a company controlled by Mr. Weinbach's adult son for certain human resource communications services. Mr. Weinbach owns 12.5% of that company. The services were satisfactorily performed at prices that the Corporation believes were reasonable and customary. The total payments made by the Corporation under the contract were $153,150.

During 2002, Merrill Lynch, through certain of its subsidiaries, provided to the Corporation in the ordinary course of business, investment banking,financial advisory and other services. The Corporation expects to continue engaging Merrill Lynch to provide similar services in 2003. Director Komansky is the chairman and former CEO of Merrill Lynch.